🔗 Permalink

Inventor profile of:

Peter A. Seubert

City:

San Francisco, California

Country:

United States

Published Applications:

Last publication date:

2025-08-28

Top Assignees for applications by Peter A. Seubert

The entities that hold a legal rights for patent applications filed by inventor Seubert Peter A.:

ELAN PHARMACEUTICALS, INC. 9 South San Francisco, CA United States
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 9 Knoxville, TN United States
Onclave Therapeutics 3 Dublin, Ireland
ONCLAVE THERAPEUTICS LIMITED 2 DUBLIN, Ireland
PROTHENA THERAPEUTICS LIMITED 1 CO. DUBLIN, Ireland
PROTHENA THERAPEUTICS LIMITED 1 DÚN LAOGHAIRE, CO. DUBLIN, Ireland
Brigham and Women's Hospital 1 Boston, MA United States

Recent patent applications by Seubert Peter A.

Peter A. Seubert from San Francisco, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-28

US20250268999A1

Human necessities

Treatment and Prophylaxis of Amyloidosis

#2 | 2021-01-14

US20210008185A1

Human necessities

Treatment and Prophylaxis of Amyloidosis

#3 | 2018-12-20

US20180360934A1

Human necessities

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#4 | 2017-03-23

US20170081396A1

Chemistry; metallurgy

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#5 | 2015-06-11

US20150158937A1

Chemistry; metallurgy

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#6 | 2014-05-15

US20140134103A1

Chemistry; metallurgy

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#7 | 2012-12-20

US20120321555A1

Human necessities

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#8 | 2012-07-26

US20120189624A1

Human necessities

Detection of amyloid deposits using anti-amyloid antibodies

#9 | 2012-02-16

US20120039878A1

Human necessities

Anti-amyloid antibodies

#10 | 2011-09-15

US20110224408A1

Human necessities

TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS

#11 | 2011-09-08

US20110218328A1

Human necessities

Chimeric, humanized, or human antibody 2A4

#12 | 2011-08-09

US10335035

Methods for determining whether a compound alters the amount of at least one αβ (X-41) peptide and the amount of either total αβ or at least one αβ (X-40) peptide produced by a non-human mammal

#13 | 2011-02-17

US20110038790A1

Human necessities

Treatment and prophylaxis of amyloidosis

#14 | 2009-08-13

US20090202432A1

Human necessities

Chimeric, humanized, or human antibody 2A4

#15 | 2007-03-06

US10746473

Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence

InventorID:

761786 ⎘